Home HOMEPAGE   Tue, 10/22/2019 GMT + 7
    Q & A   Site map Forum   Site map Sitemap   E-mali Contact   Vietnamese Vietnamese
IMPE-QN
Web Sites & Commerce News - Events
Web Sites & Commerce Introduction
Web Sites & Commerce Collaborative activities
Web Sites & Commerce Training
Web Sites & Commerce Specific research studies
Web Sites & Commerce Publications
Web Sites & Commerce Mass organization activities
Web Sites & Commerce Legal documents
Web Sites & Commerce Statistical data
Web Sites & Commerce Work safety
Web Sites & Commerce Vietnam`s Physicians
Finance & Retail Malariology
Epidemiology
Malaria parasitology
Entomology
Diagnosis and Treament
Antimalarial drugs and drug resistant parasites
Malaria Vaccines
Health education and communication
Molecular - biology
Web Sites & Commerce Helminthology
Web Sites & Commerce Other vector-borne diseases

SEARCH

LOGIN
Username
Password

WEBLINKS
Other links

Visiting users: 128
3 9 0 6 8 4 4 5
Online
1 2 8
 Malariology Malaria Vaccines
CREDIT: SHUTTERSTOCK
Malaria vaccine: How good is good enough?

The first malaria vaccine is set to be given the green light by regulators o­n Friday, opening the door for the World Health Organization to recommend its use in developing countries. But in this week's Scrubbing Up, By Dr Seth Berkley, chief executive officer of Gavi (the Vaccine Alliance), and Dr Mark Dybul, executive director of the Global Fund to Fight Aids, Tuberculosis and Malaria, say it won't be a straightforward decision.

 

How effective does a vaccine have to be before it should be made available?

This is far from straightforward. Clearly it needs to be capable of preventing disease, but to what extent?

None are 100% effective. So in the cold light of day, for most countries it comes down to a complex calculation based o­n the cost effectiveness, lives saved, illness avoided and the availability of other effective interventions.

For highly effective vaccines - o­nes which offer a high level of immunity - this normally proves uncontentious, but what about o­nes that are less effective?

How much protection do they need to provide in order to justify their use?

Such is the question World Health Organization (WHO) experts will now be preparing to ask themselves as they consider whether or not to recommend the world's first malaria vaccine for use in affected countries in Africa.

That's because, o­n Friday, the European Medicines Agency is effectively giving the GlaxoSmithKline (GSK) vaccine - called Mosquirix - a green light, meaning that the 250,000-page application has now passed every regulatory bar required of it for WHO to consider it. The decision is expected in October.

'Many unknowns'

With nearly 200m cases of malaria every year, resulting in the deaths of around 1,200 children every day, this may seem like a no brainer. However the decision is a complex o­ne.
         Clinical trial data suggests that Mosquirix offers o­nly partial protection, preventing o­ne in three cases of clinical malaria, a relatively low success rate compared to other approved vaccines.

What's more, the clinical trials were carried out with the vaccine used in conjunction with high use of other interventions, such as long-lasting insecticide treated bed-nets and anti-malarial drugs.

So we don't really know how effective the vaccine is by itself or how well it would perform outside the controlled setting of a clinical trial.

In fact there are still many unknowns.

We don't know, for example, if the vaccine will give people a false sense of security and lead to reduction in the use of bed-nets and other interventions.

'No better alternative'

Given the progress that has been made since 2000 in halving the number of malaria deaths, that would be tragic.

Similarly, the effectiveness is very much dependent upon children receiving an additional booster shot, after an initial three doses.

Without this protection starts to wane significantly from 36% efficacy with the booster to around 28% in older children, the equivalent of preventing o­ne in four cases, and even lower in younger children.

The obvious answer is to make sure everyone gets that booster, but that's easier said than done.

With vaccinations half the challenge is making sure everyone gets the full course.

That's all very well in the controlled setting of clinical trials, but in practice what sort of dropout rate can we expect for that booster shot, particularly since this will be given outside of the normal childhood immunisation schedule?

So, with such unanswered questions it may seem more prudent to hold off, focus o­n current tools with known cost effectiveness and wait for a better alternative.

The problem is that there currently aren't any. Mosquirix is about five to 10 years ahead of any other candidate malaria vaccines, and there's no guarantee any of them will be better.

Moreover, in clinical trials Mosquirix still prevented o­n average 1,774 cases of malaria per 1,000 children (with more than o­ne malaria episode per child), meaning that in areas of high burden it prevented several episodes of malaria per child per year.

Real life

So, if Mosquirix can potentially save lives or reduce illness now - even if o­nly in o­ne in three cases - then can we really justify holding off?
         Indeed, governments of malaria-affected countries are keen to see a malaria vaccine soon.

For many countries malaria is a hugely important issue and a big drain o­n their economies.

Not o­nly does it kill 584,000 people every year, the vast majority being African children under the age of five, but through recurring sickness it takes many adults out of work for prolonged periods.

All these factors conspire to make the WHO decision incredibly complex.

The best way to get any clarity o­n these issues is to see how the vaccine performs in a real-life setting, in high and low transmission areas, with and without high coverage of other interventions.

Normally this kind of post-market surveillance, or phase four trial, is used to gather additional long-term safety data.

But for Mosquirix it now seems clear that this is the o­nly way to find out definitively the role this vaccine has to play in reducing the disease burden of malaria.

Currently, several phase four trials have been proposed for Mosquirix, some of which aim to shed more light o­n its effectiveness and the issues around the booster dose, yet none of these studies are fully-funded.

That has to change. Most of the uncertainty surrounding this important vaccine concern questions that can be answered.

Given the vast scale of the number of people affected, we have a duty to fill these gaps in our knowledge.

 

07/25/2015
(Source: http://www.bbc.com)  

Announcement

LIBRARY
Book
Magazine
Document
Photos
Thesis
Documentary form
Research studies
PROFFESSIONAL SOFTWARE
Malaria forecast & management
Document management
Personel management
LEGAL DOCUMENTS
Law
Decision
Decree
Instruction
Circular
Official document
Reports
Others
SPECIFIED IMFORMATION
Malaria facts
Malaria epidemic
Petechial fever
HEALTH SERVICES
Hospital & medical centre
Drugstore
Surgery
Your doctor

Institue of Malariology Parastology and Entomology Quy Nhon
Address: 611B Nguyen Thai Hoc Str,. Quy Nhon City
Tel: (84) 056 846571 Fax: (84) 056 846755
• Designed by Quang Ich JSC